Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab in PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma
NCT07565389Phase 2Not yet recruiting
- Sponsor
- National University Hospital
- Start
- May 2026
- Primary completion
- May 2031
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab in nasopharyngeal carcinoma (NPC), sponsored by National University Hospital. Planned start May 2026; status: not yet recruiting.
02
Drugs
ivonescimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT07565389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07565389.